A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 06 May 2025
At a glance
- Drugs LY 3541860 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 22 Apr 2025 Status changed from not yet recruiting to recruiting.
- 10 Mar 2025 New trial record